Evidence review shows positive results for Negative Pressure Wound Therapy (NPWT) on surgical incisions

By PR Newswire,  January 22, 2014, 08:00:00 AM EDT


ST. PETERSBURG, Fla., Jan. 22, 2014 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE:SNN), the global medical technology business, announces today a review of 33 published papers that shows fewer wound healing complications in patients with closed surgical incisions after Negative Pressure Wound Therapy (NPWT) is applied for three to five days post surgery. The journal Bone and Joint Research published the review, which was written by an international panel of experts on NPWT.  

"According to a consensus of the randomised studies, there is a strong argument for the preventative use of NPWT on high-risk, closed surgical incisions," said  Prof. James Stannard,  Professor and Orthopaedic Surgeon at the Missouri Orthopaedic Institute at the University of Missouri, a co-author of the paper and the first surgeon ever to report the use of NPWT on closed incisions.

"Most surgeons are  familiar with the efficacy of NPWT on complex open wounds as that has become a standard of care," said Prof. Stannard. "However, there is a growing awareness of the potential for incisional NPWT to reduce post surgical complications in high risk patients and the related costs involved.  We expect that the further development of lower cost, single use NPWT devices will catalyse additional studies."

The most common surgical site complication is infection.  According to the U.S. Centers for Disease Control and Prevention, about 300,000 surgical site infections (SSIs) occur every year in the United States, representing 17% of all healthcare associated infections. SSIs occur in an estimated 5% of in-patient surgical procedures and result in seven to 10 additional post-operative hospital days. (Berrios-Torres SI. Surgical Site Infection (SSI) Toolkit. Activity C: ELC Prevention Collaboratives. U.S. Centers for Disease Control and Prevention (CDC); 2009. Available here.)   

Co-authored by six members of a panel of international experts on NPWT, the Bone and Joint Research paper examines research from 33 clinical publications investigating new technologies that can be applied to closed surgical incisions to help minimise complications. The panel conducted the review in orthopaedic and other surgical disciplines.

The paper's co-authors are currently completing independent investigator initiated studies with PICO, Smith & Nephew's single use NPWT system.

"Single use NPWT devices such as Smith & Nephew'sPICO mean that the lower cost of therapy can create many more opportunities for building clinical evidence in large randomised studies," said Dr. Robin Martin, a co-author of the paper and Director of Clinical Sciences at Smith & Nephew. "For a future article, we plan to assess the evidence for identifying those patients at greatest risk of surgical site complications in orthopaedic procedures and review the guidelines to target certain patient groups with NPWT as a preventive technology.  We plan to examine the economic implications for such an approach as well."

Bone and Joint Research is a UK-based peer reviewed journal that publishes papers across the entire spectrum of musculoskeletal sciences.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma, Smith & Nephew has around 11,000 employees and a presence in more than 90 countries. Annual sales in 2012 were more than $4.1 billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE:SNN).

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payors and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; strategic actions, including acquisitions and dispositions, our success in integrating acquired businesses, and disruption that may result from changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors.

Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.  

 Trademark of Smith & Nephew.  Registered US Patent and Trademark Office.

SOURCE Smith & Nephew



This article appears in: News Headlines

Referenced Stocks: SNN


Latest News Video





Most Active by Volume

Company Last Sale Change Net / %
BAC $ 16.13 0.26 ▼ 1.59%
FB $ 59.72 0.63 ▲ 1.07%
YHOO $ 36.35 2.14 ▲ 6.26%
INTC $ 26.93 0.16 ▲ 0.60%
SIRI $ 3.17 0.08 ▲ 2.59%
QQQ $ 86.18 1.13 ▲ 1.33%
AA $ 13.42 0.37 ▲ 2.84%
GE $ 26.12 0.30 ▲ 1.16%

As of 4/16/2014, 04:05 PM